What does the evidence say about Astragalus Immune Support Meta-Analysis?

The current Migaku evidence database contains 2 reusable source documents for Astragalus Immune Support Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation. - The medical burden associated with acute exacerbations has become a major public health challenge (). [Zhang Qianqian (2026); evidence level 1] - Poor long-term control leads to progressive decline in lung function, increasing the risk of acute exacerbations and death (). [Zhang Qianqian (2026); evidence level 1] - However, clinical challenges remain: long-term ICS use may lead to adverse effects such as osteoporosis (), 10%–15% of patients have “refractory asthma” (), overuse of SABA is associated with disease exacerbation (), and some patients exhibit poor medication adherence. [Zhang Qianqian (2026); evidence level 1] - et al., 2025 Huang et al., 2019 Eger et al., 2022 Bronchial asthma is a highly prevalent respiratory disease worldwide, characterized by chronic airway inflammation, airway hyperresponsiveness, reversible airflow limitation, and airway remodeling, driven by both genetic and environmental factors (). [Zhang Qianqian (2026); evidence level 1] - 5 6 7 8 9 Aging is accompanied by a progressive decline in cellular and organ function, leading to an increased incidence of chronic diseases and neurodegenerative disorders. [Kanubaddi Kiran Reddy (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.